Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Hollis Eden Pharmaceuticals Inc. (HEPH) -- Ignore unavailable to you. Want to Upgrade?

To: BDR who wrote (3)	2/10/1998 2:14:00 AM
From: Druss	Read Replies (1) \| Respond to of 138

Dale--I have been trying to find out what is going on with this company too. It looks very much like a short to me, but it looks like it was a good short at 10 too. I found this summary which is not profound but sums up the company very accurately: <<Hollis-Eden Pharmaceuticals, Inc. is a development stage pharmaceutical company engaged in developing therapeutic and/or preventative pharmaceutical agents for the treatment of a number of targeted disease states caused by viral, bacterial, parasitic or fungal infections, including HIV and AIDS.>> A development stage biotech shouldn't be suddenly tearing up the charts. This company is likely 2-3 years from phase 3 work being completed at best. I thought there may be a hype job going on on one of the Yahoo threads but found no thread devoted to the company. Perhaps on AOL, I don't have access to those threads. I have been researching the devil out of this thing. No news published in the major newspapers, no news in major magazines, in fact it is difficult to find much at all. It has negligible profits, significant losses, and little information. The Stanford scientist joined a month and a half or so ago, if he was the reason it is the biggest delay I have ever seen in the market. I would short it but I wouldn't take a position until I have some idea why the run up. All the Best Druss

To: BDR who wrote (3)	2/14/1998 5:59:00 PM
From: zevach2	Read Replies (1) \| Respond to of 138

Ruff Times Newsletter. Howard Ruff has been hyping this stock as a $20 or $30 stock beginning in January 98. A full report on the company was written up in the February issue. At least that is what my mom told me today (she was giving me an unsolicited stock tip). She is retired and I assume a lot of the older (>65) generation read this newsletter as Howard was quite popular in the early 80s. He was selling lifetime subscriptions for $1800 then. I would assume the run up has been caused by his newsletter and the intriguing nature of the drugs in the HEPH pipeline.